| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
Galectin-8
Galectin-8-IN-1 specifically targets the galectin-8 N-terminal domain (galectin-8N). It binds to this domain with a dissociation constant (Kd) of 48 μM, showing 15-fold selectivity over galectin-3 and even higher selectivity over other mammalian galectins. |
|---|---|
| ln Vitro |
In vitro, Galectin-8-IN-1 is a selective ligand for the galectin-8 N-terminal domain (galectin-8N), with a Kd of 48 μM. Its selectivity is 15 times that of galectin-3 and even greater than for other mammalian galectins.
|
| ln Vivo |
Specific in vivo activity data for Galectin-8-IN-1 are not provided in the available literature. As a selective ligand, its primary application is likely in studying the role of galectin-8 in biological processes such as tumor progression, lymphangiogenesis, immune modulation, and autophagy.
|
| Enzyme Assay |
Non-cellular binding assays for Galectin-8-IN-1 involve measuring its affinity for the galectin-8N domain. Techniques such as surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC) are used to determine the dissociation constant (Kd) of 48 μM and to assess its selectivity over other galectins.
|
| Cell Assay |
In vitro cellular assays for Galectin-8-IN-1 would involve treating cells with the compound to study its effects on galectin-8-mediated functions. This could include assessing its impact on cell adhesion, migration, proliferation, or signaling pathways that are modulated by galectin-8.
|
| Animal Protocol |
In vivo animal experiments for Galectin-8-IN-1 are not described in the provided sources. Given galectin-8's involvement in tumor progression and immune modulation, such studies could involve tumor-bearing mouse models to evaluate the compound's effects on tumor growth and metastasis.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties for Galectin-8-IN-1 are not detailed in the available literature. As a small molecule ligand, its PK profile would be important for understanding its bioavailability and suitability for in vivo studies.
|
| Toxicity/Toxicokinetics |
Toxicological data for Galectin-8-IN-1 are not provided in the available sources. As a research compound, its safety profile has not been extensively characterized. It is intended for research use only and not for human consumption.
|
| References | |
| Additional Infomation |
Galectin-8-IN-1 has a molecular weight of 334.32 and a molecular formula of C16H18N2O6. Its CAS number is 3028946-23-5. It is supplied for research purposes only.
|
| Molecular Formula |
C16H18N2O6
|
|---|---|
| Molecular Weight |
334.32
|
| Exact Mass |
334.116
|
| CAS # |
3028946-23-5
|
| PubChem CID |
162368298
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
24
|
| Complexity |
487
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
CN1C2=C(C=CC(=C2)C(=O)O)N=C1CO[C@@H]3C=CO[C@@H]([C@@H]3O)CO
|
| InChi Key |
QQZYRRIGHJNGGY-UMVBOHGHSA-N
|
| InChi Code |
InChI=1S/C16H18N2O6/c1-18-11-6-9(16(21)22)2-3-10(11)17-14(18)8-24-12-4-5-23-13(7-19)15(12)20/h2-6,12-13,15,19-20H,7-8H2,1H3,(H,21,22)/t12-,13-,15-/m1/s1
|
| Chemical Name |
2-[[(2R,3R,4R)-3-hydroxy-2-(hydroxymethyl)-3,4-dihydro-2H-pyran-4-yl]oxymethyl]-3-methylbenzimidazole-5-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9911 mL | 14.9557 mL | 29.9115 mL | |
| 5 mM | 0.5982 mL | 2.9911 mL | 5.9823 mL | |
| 10 mM | 0.2991 mL | 1.4956 mL | 2.9911 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA